Skip to main content
Premium Trial:

Request an Annual Quote

Activiomics Raises $800K in Funding

Premium

Biotech firm Activiomics this week said it has raised £500,000 ($806,715) in a funding round led by IP Group and joined by IP Venture Fund and members of Activiomics' management team.

The investment, which is about $200,000 short of the $1 million CEO Mark Warne in December told ProteoMonitor the company hoped to raise (PM 12/10/2010), will be used to further grow partnerships with pharma and biotech companies as well as to pursue identification of prognostic and diagnostic protein biomarkers for cancer, the company said.

Activiomics' main technology platform is its TIQUAS, or targeted in-depth quantification of cell signaling, system – a label-free, LC-MS/MS-based approach to quantifying levels of phosphorylated proteins in material like cells or human tissue. The company's proprietary Pescal software enables researchers to quantify identified peptides by automatically extracting their elution profiles and generating extracted ion chromatograms for each.

Since launching in February 2010, the firm has announced two pharma deals – a project for GlaxoSmithKline investigating phosphorylation patterns related to inflammatory stimulus and steroid treatment (PM 04/23/2010), and an agreement with biopharma firm UCB to study cell signaling pathways targeted by therapeutic antibodies.

In December, Warne said the company was negotiating other agreements for cell signaling analysis work, including one with a large biopharma company that it hoped to announce early this year, but as of yet no additional announcements have been made.

In addition to doing fee-for-service work, Activiomics is also pursuing its own internal protein biomarker studies with the ultimate aim of developing proprietary diagnostics.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.